parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in retinal ganglion cells	0.75
chemistry Open Targets	reachable by antibody	0.36
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 24	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 10681

receipt 10689: VWC2 in dopamine neurons, braak

power: full sample +0.17 (p 0.493, n 18), 95% CI -0.32 to +0.59. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.03 (p 0.922, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.05 (p 0.840, n 18). could be the mix.
skeptic: leave-one-out range +0.09 to +0.30, sign flips 0; without severely affected donors +0.17 (p 0.493, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for VWC2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 10688: VWC2 in oligodendrocytes, braak

power: full sample -0.08 (p 0.748, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.06 (p 0.814, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.23 (p 0.369, n 18). could be the mix.
skeptic: leave-one-out range -0.17 to +0.05, sign flips 3; without severely affected donors -0.08 (p 0.748, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for VWC2 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts